Asmerom T Sengal Multi-Omics Conference 2024

Asmerom T Sengal

I am a clinician scientist passionate about improving patient outcomes through innovative research. I graduated with Doctor of Medicine (MD) in 2009 and completed my specialization in Anatomic Pathology. I have published more than 20 articles and conference papers in peer-reviewed international journals. My research is focused on biomarker discovey, preclinical model development and drug screening. I developed and validated novel BaseScope RNA ISH techniques and using this assay I revealed FGFR2c is an independent prognostic and predictive biomarker. I established and characterised 24 EC PDXs and 16 PDX-derived organoids (PDXOs) that are vital for drug testing (Pub1 and 2 D1 Journals). Using the established PDXs and PDXOs, I revealed FGFR2c is a novel target in EC. I have also demonstrated the dependency of the EC organoid growth on FGFR2c/FGF2 signalling using FGFR2 shRNA-mediated knockdown. Recently, as part of my CCAF funding, I developed a unique cohort of 25 EC PDOs from metastatic/recurrent EC and matched primary representing the different molecular subtypes. I have established CPDOs and TriPDOs that represent the TIME and the proposed study is a natural continuation of well-established project. I have also established extensive network of collaboration with clinicians, pathologist and lab scientists nationally and internationally. I secured more $420, 000 funding as CIA or CIB from diffren funding bodies including an industry and my work contributed to $750 US DOD funding to the Pollock Lab. In recognition of my milestone achievements, I was granted my academic promotion, invited to speak at different conferences, recruited academic editor in PLOS One and awarded Cure Cancer Research of the Year 2024 (finalist).